Select the Right Partner
Assess capability, quality systems, resources, compliance history and operational control before delegating critical regulated activities.
Independent qualification and oversight audits for CROs, laboratories, manufacturers, technology providers, consultants and other critical third parties supporting regulated life sciences activities.
Vendor audits evaluate whether third parties can consistently meet contractual, operational, quality and regulatory expectations before selection and throughout the relationship.
Assess capability, quality systems, resources, compliance history and operational control before delegating critical regulated activities.
Evaluate whether vendors continue to meet agreed expectations and whether emerging performance or compliance risks are identified early.
Improve quality agreements, escalation, performance monitoring, change notification and documented sponsor or client oversight.
Vendor risk often becomes visible when responsibilities are unclear, performance monitoring is weak or critical issues are not escalated through a documented governance process.
A vendor is selected without adequate assessment of capability, systems, resources, compliance maturity or delivery risk.
Contracts and quality agreements do not define ownership, communication, escalation, change notification or evidence expectations clearly.
Quality metrics, service reviews, deviations, complaints and recurring problems are not analyzed or escalated consistently.
Vendor corrective actions are accepted without sufficient root cause challenge, evidence verification or effectiveness assessment.
Audit scope can be adapted to the type of vendor, delegated activity, regulatory framework, contractual exposure and criticality of the service provided.
Independent assessment of clinical operations, project governance, monitoring, data management, safety interfaces and sponsor-facing oversight evidence.
Qualification and oversight audits for central, bioanalytical, nonclinical, quality-control and specialty laboratories.
Independent review of contract manufacturers and development organizations supporting regulated products and processes.
Evaluation of providers supporting eClinical, laboratory, manufacturing, safety, document-management and other regulated computerized environments.
Assessment of specialist service providers performing delegated quality, regulatory, safety, statistical, medical or operational work.
Focused independent assessment when repeated failures, critical deviations, data concerns or service-performance issues require urgent review.
The final scope is adapted to vendor criticality, delegated responsibilities, applicable GxP framework and the business purpose of the audit.
The engagement process is designed to provide objective evidence, risk-based conclusions and practical recommendations for qualification and ongoing oversight.
Understand the delegated service, vendor criticality, regulatory exposure, contractual model and known performance risks.
Define objectives, criteria, systems, processes, documentation, interviewees and areas requiring deeper assessment.
Review contracts, quality agreements, procedures, metrics, previous audits, deviations and available performance information.
Conduct interviews, process walkthroughs, system demonstrations, document review and evidence-based record sampling.
Assess the significance of findings and determine whether the vendor is suitable for qualification, continuation or expanded scope.
Deliver risk-ranked findings, recommendations and optional CAPA review or effectiveness verification.
Deliverables can be adapted to vendor selection, requalification, routine oversight, remediation or for-cause review.
Vendor audits can support selection, ongoing governance, remediation, transaction due diligence or urgent independent review.
A critical third party requires independent assessment before contracting or service initiation.
An existing vendor requires reassessment based on risk, time or expanded responsibilities.
Metrics, delays, deviations or complaints indicate declining control or delivery quality.
A vendor will take on additional regulated activities, systems or markets.
Sponsor or client oversight of critical vendors may receive regulatory scrutiny.
Third-party records, systems or data transfers require focused independent review.
A strategic partner or outsourced operating model requires compliance and quality-risk assessment.
Serious vendor failures require confidential, focused and independent assurance.
Independent vendor audits support better selection, stronger oversight and earlier identification of risks that could affect compliance, product quality, patient safety or business continuity.
Make qualification decisions using objective evidence about capability, compliance maturity and operational control.
Improve responsibility clarity, performance monitoring, escalation and quality-agreement execution.
Identify declining performance, recurring failures and emerging compliance risks before they become larger business issues.
Common questions from sponsors, pharmaceutical organizations, CROs and regulated companies considering independent vendor audit support.
Yes. Depending on the service, systems and available documentation, vendor audits can be delivered remotely, onsite or through a hybrid model.
Yes. Audits can cover CROs, laboratories, CMOs, CDMOs, technology providers, consultants and other regulated service providers.
Yes. Deliverables can include a suitability assessment, risk classification, approval conditions and recommendations for qualification or remediation.
Yes. The audit can evaluate whether responsibilities, escalation, change notification, performance monitoring and audit rights are adequately defined.
Yes. Support can include root cause challenge, CAPA adequacy review, evidence verification and follow-up effectiveness assessment.
Yes. Vendor audit engagements are handled confidentially, and NDA-based collaboration can be used where required.